Lorlatinib Continuation Study
The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit further characterization of the safety profile of lorlatinib in participants continuing to receive study intervention
Checked against the public recordLast updated Aug 26, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 4
- Sponsor
- Pfizer
- Interventions being studied
- Drug: Lorlatinib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1 - Any participant who is receiving study treatment and deriving clinical benefit (as determined by the Principal Investigator) in a Pfizer-sponsored Lorlatinib Parent Study. 2- Participants must agree to follow the reproductive criteria. 3- Adequate Bone Marrow, Liver, Renal, Pancreatic Function Exclusion Criteria: 1 - Female participants who are pregnant or breastfeeding. 2- Any medical reason that, in the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the study.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine, California
- The First affiliated Hospital of Anhui Medical UniversityHefei, Anhui
- Beijing Chest Hospital, Capital Medical UniversityBeijing, Beijing Municipality
- Beijing Cancer HospitalBeijing, Beijing Municipality
- Fujian Cancer HospitalFuzhou, Fujian
- Guangdong Provincial People's HospitalGuangzhou, Guangdong
- Hunan Provincial Tumor HospitalChangsha, Hunan
- General Hospital of Eastern Theater CommandNanjing, Jiangsu
- Jilin Cancer HospitalChangchun, Jilin
- The first hospital of jilin universityChangchun, Jilin
- Sir Run Shaw HospitalHangzhou, Qiantang District
- The Second Affiliated Hospital of PLA Air Force Medical UniversityXi'an, Shaanxi
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 26, 2026. Always confirm current availability with the study team.